X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-27 | VIRX | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $0.73 | -3,405 | 102,306 | -3% | -$2,493 | |||||
| M | 2023-11-30 | VIRX | Rothera Mark | Pres, CEO | P - Purchase | $0.49 | +100,000 | 100,000 | New | +$49,362 | |||||
| D | 2023-11-28 | VIRX | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $0.50 | -3,720 | 98,822 | -4% | -$1,860 | |||||
| D | 2023-08-28 | VIRX | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $1.45 | -3,512 | 95,653 | -4% | -$5,092 | |||||
| D | 2023-05-25 | VIRX | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $1.42 | -3,635 | 92,277 | -4% | -$5,160 | |||||
| D | 2023-02-27 | VIRX | Rojkjaer Lisa | Chief Medical Officer | S - Sale+OE | $1.68 | -2,156 | 48,087 | -4% | -$3,625 | |||||
| D | 2023-02-27 | VIRX | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $1.68 | -3,599 | 89,023 | -4% | -$6,051 | |||||
| D | 2022-11-28 | VIRX | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $2.72 | -3,532 | 85,733 | -4% | -$9,606 | |||||
| D | 2022-11-28 | VIRX | Rojkjaer Lisa | Chief Medical Officer | S - Sale+OE | $2.72 | -2,116 | 46,116 | -4% | -$5,754 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |